Navigation Links
WuXi AppTec and QIAGEN Enter into Partnership Agreement for Molecular Biomarker Development

SHANGHAI, Jan. 10 /PRNewswire-Asia/ -- WuXi AppTec Inc. today announced that it has entered into a partnership with QIAGEN to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases. QIAGEN will provide a complete portfolio of instrumentation, training, and consumables and WuXi AppTec will provide laboratory facilities and staff to execute the services. The laboratory will be located at WuXi AppTec's campus in Shanghai and will begin operating immediately.

(Logo: )

Under the terms of the partnership agreement, WuXi AppTec will also work with QIAGEN to help develop biomarkers, assay panels, personalized healthcare diagnostics, and other products that QIAGEN intends to bring to market. WuXi AppTec will use QIAGEN's technologies for a broad range of applications in support of drug discovery and development on behalf of the company's and QIAGEN's customers. WuXi AppTec and QIAGEN will also co-promote each other's services to their respective customers. Both companies are working closely to identify additional opportunities to deepen their relationship.

"WuXi AppTec has long been interested in partnering with a premier international molecular biotechnology company like QIAGEN to support the development of our biomarker business," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "This partnership gives us access to innovative technologies and processes that will allow us to better serve our customers."

"We are very pleased to have entered into this partnership with WuXi AppTec, a global leader in providing integrated research and development services to the pharmaceutical industry," said Dr. Victor Shi, President, Asia Pacific of QIAGEN. "In doing so, we have created what we believe to be the first laboratory of its kind in Asia equipped with a standardized, fully integrated, automated sample and assay technology platform for drug discovery and development and molecular diagnostics in personalized healthcare and other areas. We believe that this partnership is a significant milestone in providing high-quality and complete automated solutions for the molecular biomarker testing industry."

About WuXi AppTec:

WuXi AppTec is a leading pharmaceutical, biotechnology, and medical-device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing services throughout the pharmaceutical and medical-device R&D process. WuXi AppTec's services are designed to help its global partners to improve the success, shorten the time, and reduce the cost of research and development.

Web: .


QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing, and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digeneHPV Test, which is regarded as a "gold standard" in testing for high- risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,400 people in over 30 locations worldwide. Further information about QIAGEN can be found at

    For further information, please contact:

    WuXi AppTec Inc.
    Ronald Aldridge
    Director of Investor Relations
    Tel:   +1-201-585-2048

SOURCE WuXi AppTec Inc.



SOURCE WuXi AppTec Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
2. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
3. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
4. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
5. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
6. University of Pittsburgh Medical Center (UPMC) Treats 10,000th Patient with Leksell Gamma Knife Radiosurgery System
7. Baylor Adds Naviscan PEM Technology to Womens Imaging Center
8. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
9. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
10. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
11. Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
Post Your Comments:
(Date:11/25/2015)... 2015 Allergan plc (NYSE: AGN ... Therapeutics, a start-up  biotechnology company focused on the ... and funded by the F-Prime Biomedical Research Initiative ... an exclusive collaboration to support the discovery and ... (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
(Date:11/25/2015)... 2015 Asia -based ... BioLight and the New Investors will make a direct ... a private placement. The financing will help IOPtima to ... used in the treatment of glaucoma, as well as ... IOPtimate™ system with the U.S. Food and Drug Administration, ...
Breaking Medicine Technology:
(Date:11/26/2015)... , ... November 26, 2015 , ... Jobs in hospital ... healthcare professionals and offered by healthcare staffing agency Aureus Medical Group . ... month of October 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Indosoft Inc., developer ... of an application server to improve system efficiency and reliability. , The new Q-Suite ... of these standards, the system avoids locking itself into a specific piece of software ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of ... its stellar workplace culture with the company’s Cincinnati office being named a finalist ... office was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health ... launches new Wimbledon Athletics Facebook page to educate the public, parents ... cardiac abnormalities. About 2,000 people under the age of 25 die from sudden ...
Breaking Medicine News(10 mins):